Advertisement

Tumor Biology

, Volume 37, Issue 11, pp 15203–15210 | Cite as

The anticancer effects of Resina Draconis extract on cholangiocarcinoma

Original Article

Abstract

Cholangiocarcinoma (CCA) is a relatively rare, heterogeneous malignant tumor with poor clinical outcomes. Because of high insensitivity to chemotherapy and radiotherapy, there are no effective treatment options. Efforts to identify and develop new agents for prevention and treatment of this deadly disease are urgent. Here, we assessed the apoptotic cytotoxicity of Resina Draconis extract (RDE) using in vitro and in vivo assays and identified the mechanisms underlying antitumor effects of RDE. RDE was obtained via vacuum distillation of Resina Draconis with 75 % ethanol. The ethanol extract could inhibit CCA cell proliferation and trigger apoptotic cell death in both QBC939 and HCCC9810 cell lines in a time- and concentration-dependent manner. RDE treatment resulted in intracellular caspase-8 and poly (ADP-ribose) polymerase protease activation. RDE significantly downregulated antiapoptotic protein survivin expression and upregulated proapoptotic protein Bak expression. RDE also inhibited CCA tumor growth in vivo. We observed that human CCA tissues had much higher survivin expression than did paired adjacent normal tissue. Taken together, the current data suggested that RDE has anticancer effects on CCA, and that RDE could function as a novel anticancer agent to benefit patients with CCA.

Keywords

Resina Draconis Cholangiocarcinoma Apoptosis Survivin Anticancer 

Notes

Acknowledgments

This work was financially supported, in part, by the National Natural Science Foundation of China no. 31371425 to X. Zhao and no. 31240025 to Z. Lu and the National Science and Technology Major Projects for Major New Drugs Innovation and Development of China 2012ZX09303015 to Q. Guo.

Compliance with ethical standards

Conflicts of interest

None

Ethical standards

All the experiments involving in human specimens and animal were in accordance with protocols approved by the Ethical Committee for Human and Animal Experiments Guidelines on Animal Welfare of the China Medical University Shengjing Hospital (Shenyang, Liaoning, China).

Informed consent

Informed consent was obtained from all patients for being included in the study.

References

  1. 1.
    Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013;153:38–55.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lubezky N, Facciuto M, Harimoto N, Schwartz ME, Florman SS. Surgical treatment of intrahepatic cholangiocarcinoma in the USA. J Hepatobiliary Pancreat Sci. 2015;22:124–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Bartella I, Dufour JF. Clinical diagnosis and staging of intrahepatic cholangiocarcinoma. J Gastrointestin Liver Dis. 2015;24:481–9.PubMedGoogle Scholar
  4. 4.
    Ruzzenente A, Conci S, Valdegamberi A, Pedrazzani C, Guglielmi A. Role of surgery in the treatment of intrahepatic cholangiocarcinoma. Eur Rev Med Pharmacol Sci. 2015;19:2892–900.PubMedGoogle Scholar
  5. 5.
    Zhu AX. Future directions in the treatment of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29:355–61.CrossRefPubMedGoogle Scholar
  6. 6.
    Lalaoui N, Lindqvist LM, Sandow JJ, Ekert PG. The molecular relationships between apoptosis, autophagy and necroptosis. Semin Cell Dev Biol. 2015;39:63–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Fulda S. Targeting apoptosis for anticancer therapy. Semin Cancer Biol. 2015;31:84–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Alsanad SM, Williamson EM, Howard RL. Cancer patients at risk of herb/food supplement-drug interactions: a systematic review. Phytother Res. 2014;28:1749–55.CrossRefPubMedGoogle Scholar
  9. 9.
    Yeung KS, Gubili J. Clinical guide to herb-drug interactions in oncology. J Soc Integr Oncol. 2007;5:113–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Xu W, Debeb BG, Lacerda L, Li J, Woodward WA. Tetrandrine, a compound common in Chinese traditional medicine, preferentially kills breast cancer tumor initiating cells (TICs) in vitro. Cancers (Basel). 2011;3:2274–85.CrossRefGoogle Scholar
  11. 11.
    Jang SY, Hong D, Jeong SY, Kim JH. Shikonin causes apoptosis by up-regulating p73 and down-regulating ICBP90 in human cancer cells. Biochem Biophys Res Commun. 2015;465:71–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Ge L, Mao L, Tian JH, Shi FY, Lou L, Qiu X, et al. Network meta-analysis on selecting Chinese medical injections in radiotherapy for esophageal cancer. Zhongguo Zhong Yao Za Zhi. 2015;40:3674–81.PubMedGoogle Scholar
  13. 13.
    Xu J, Xiong T, Yang Y, Li J, Mao J. Resina Draconis as a topical treatment for pressure ulcers: a systematic review and meta-analysis. Wound Repair Regen. 2015;23:565–74.CrossRefPubMedGoogle Scholar
  14. 14.
    Liu H, Lin S, Xiao D, Zheng X, Gu Y, Guo S. Evaluation of the wound healing potential of Resina Draconis (Dracaena cochinchinensis) in animal models. Evid Based Complement Alternat Med. 2013;2013:709865.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Lu H, Teng J, Wu H. A review on the study of Resina Draconis produced in China. Zhong Yao Cai. 2003;26:459–61.PubMedGoogle Scholar
  16. 16.
    Hu L, Xia L, Zhou H, Wu B, Mu Y, Wu Y, et al. TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCalpha and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620. Tumour Biol. 2013;34:2573–81.CrossRefPubMedGoogle Scholar
  17. 17.
    Peng W, Hu J, Zhu XD, Liu X, Wang CC, Li WH, et al. Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. Tumour Biol. 2014;35:2983–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Shirali S, Aghaei M, Shabani M, Fathi M, Sohrabi M, Moeinifard M. Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3. Tumour Biol. 2013;34:1085–95.CrossRefPubMedGoogle Scholar
  19. 19.
    Li Y, Xiao W, Qin J, Guo Y, Zhu Q. Simultaneous determination of five active components in Resina Draconis and its extract by HPLC. Zhongguo Zhong Yao Za Zhi. 2012;37:929–33.PubMedGoogle Scholar
  20. 20.
    Cao Y, Gong W, Li N, Yin C, Wang Y. Comparison of microemulsion electrokinetic chromatography with high-performance liquid chromatography for fingerprint analysis of Resina Draconis. Anal Bioanal Chem. 2008;392:1003–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Powell CB, Fung P, Jackson J, Dall’Era J, Lewkowicz D, Cohen I, et al. Aqueous extract of herba Scutellaria barbatae, a Chinese herb used for ovarian cancer, induces apoptosis of ovarian cancer cell lines. Gynecol Oncol. 2003;91:332–40.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhong F, Yang J, Tong ZT, Chen LL, Fan LL, Wang F, et al. Guggulsterone inhibits human cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cell growth by inducing caspase-dependent apoptosis and downregulation of survivin and Bcl-2 expression. Oncol Lett. 2015;10:1416–22.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhu ZB, Chen Y, Makhija SK, Lu B, Wang M, Rivera AA, et al. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Int J Oncol. 2006;29:1319–29.PubMedGoogle Scholar
  24. 24.
    Ye CG, Chen GG, Ho RL, Merchant JL, He ML, Lai PB. Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma. Biochim Biophys Acta. 2013;1833:2970–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    To AK, Chen GG, Chan UP, Ye C, Yun JP, Ho RL, et al. ZBP-89 enhances Bak expression and causes apoptosis in hepatocellular carcinoma cells. Biochim Biophys Acta. 1813;2011:222–30.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of RadiologyShengjing Hospital of China Medical UniversityShenyangChina

Personalised recommendations